RUA Life Sciences PLC Directorate Change (1054L)
2023年9月1日 - 4:04PM
RNSを含む英国規制内ニュース (英語)
TIDMRUA
RNS Number : 1054L
RUA Life Sciences PLC
01 September 2023
1 September 2023
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Directorate Change
RUA Life Sciences plc (AIM: RUA.L), the holding company of a
group of medical device businesses focused on the exploitation of
Elast-Eon(TM), the world leading long-term implantable biostable
polyurethane, announces that Iain Anthony, Director of Clinical and
Regulatory Affairs has tendered his resignation from the Company in
order to accept an opportunity elsewhere within the industry.
Iain joined RUA in November 2021 and has overseen the building
of the Regulatory and Quality teams together with further
development of the vascular graft device and was instrumental in
undertaking the Q-Sub process with the FDA which has recently
concluded succesfully.
Iain will step down from the board with immediate effect but
will continue in his role as an employee for an appropriate
handover period while the Board looks for his successor. The Board
thanks Iain for his contribution to the business and wish him
well.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Caroline Stretton, Group Managing Director Tel: +44 (0)1294 317073
Cenkos Securities plc (Nominated Adviser and Broker) Tel: +44
(0)20 7397 8900
Giles Balleny/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
enabling medical devices with Elast-Eon (TM) , the world's leading
long-term implantable polyurethane. Whether it is licensing
Elast-Eon (TM) , manufacturing a device or component, or developing
next generation medical devices, a RUA Life Sciences business is
pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 8
million implants and 15 years of successful clinical use, RUA's
polymers are proven in long-term life enabling applications.
The Group's four business units are:
RUA Contract Manufacture: End-to-end contract developer and manufacturer
of medical devices and implantable fabric
specialist.
RUA Biomaterials: Licensor of Elast-Eon (TM) polymers to the
medical device industry.
RUA Vascular: Commercialisation of open surgical vascular
grafts and patches
RUA Structural Development of polymeric leaflet systems
Heart: for heart valves.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADFLBBXKLBBBL
(END) Dow Jones Newswires
September 01, 2023 03:04 ET (07:04 GMT)
Rua Life Sciences (LSE:RUA)
過去 株価チャート
から 4 2024 まで 5 2024
Rua Life Sciences (LSE:RUA)
過去 株価チャート
から 5 2023 まで 5 2024